- Home
- TEAF vs CRVS Comparison
TEAF vs CRVS Comparison
Compare TEAF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- CRVS
- Stock Information
- Founded
- TEAF 2017
- CRVS 2014
- Country
- TEAF United States
- CRVS United States
- Employees
- TEAF N/A
- CRVS N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- CRVS Health Care
- Exchange
- TEAF Nasdaq
- CRVS Nasdaq
- Market Cap
- TEAF 174.8M
- CRVS 516.0M
- IPO Year
- TEAF N/A
- CRVS 2016
- Fundamental
- Price
- TEAF $11.95
- CRVS $5.10
- Analyst Decision
- TEAF
- CRVS Strong Buy
- Analyst Count
- TEAF 0
- CRVS 5
- Target Price
- TEAF N/A
- CRVS $12.38
- AVG Volume (30 Days)
- TEAF 56.1K
- CRVS 1.7M
- Earning Date
- TEAF 01-01-0001
- CRVS 11-12-2024
- Dividend Yield
- TEAF 9.20%
- CRVS N/A
- EPS Growth
- TEAF N/A
- CRVS N/A
- EPS
- TEAF N/A
- CRVS N/A
- Revenue
- TEAF N/A
- CRVS N/A
- Revenue This Year
- TEAF N/A
- CRVS N/A
- Revenue Next Year
- TEAF N/A
- CRVS N/A
- P/E Ratio
- TEAF N/A
- CRVS N/A
- Revenue Growth
- TEAF N/A
- CRVS N/A
- 52 Week Low
- TEAF $11.11
- CRVS $1.30
- 52 Week High
- TEAF $13.30
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TEAF 35.01
- CRVS 36.16
- Support Level
- TEAF $11.84
- CRVS $4.93
- Resistance Level
- TEAF $12.21
- CRVS $6.47
- Average True Range (ATR)
- TEAF 0.13
- CRVS 0.40
- MACD
- TEAF 0.01
- CRVS 0.06
- Stochastic Oscillator
- TEAF 37.04
- CRVS 29.74
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).